US3720760A
(en)
|
1968-09-06 |
1973-03-13 |
Pharmacia Ab |
Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
|
DE2031216A1
(de)
|
1969-06-19 |
1971-01-14 |
Citizen Watch Co Ltd , Tokio |
Tag und Datum Stellvorrichtung fur Uhren mit Kalender
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
US3940475A
(en)
|
1970-06-11 |
1976-02-24 |
Biological Developments, Inc. |
Radioimmune method of assaying quantitatively for a hapten
|
US3896111A
(en)
|
1973-02-20 |
1975-07-22 |
Research Corp |
Ansa macrolides
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
USRE30985E
(en)
|
1978-01-01 |
1982-06-29 |
|
Serum-free cell culture media
|
FR2413974A1
(fr)
|
1978-01-06 |
1979-08-03 |
David Bernard |
Sechoir pour feuilles imprimees par serigraphie
|
US4265814A
(en)
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
JPS5566585A
(en)
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164687A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS55164685A
(en)
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164686A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4309428A
(en)
|
1979-07-30 |
1982-01-05 |
Takeda Chemical Industries, Ltd. |
Maytansinoids
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
US4419446A
(en)
|
1980-12-31 |
1983-12-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant DNA process utilizing a papilloma virus DNA as a vector
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
NZ201705A
(en)
|
1981-08-31 |
1986-03-14 |
Genentech Inc |
Recombinant dna method for production of hepatitis b surface antigen in yeast
|
US4601978A
(en)
|
1982-11-24 |
1986-07-22 |
The Regents Of The University Of California |
Mammalian metallothionein promoter system
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4675187A
(en)
|
1983-05-16 |
1987-06-23 |
Bristol-Myers Company |
BBM-1675, a new antibiotic complex
|
DD266710A3
(de)
|
1983-06-06 |
1989-04-12 |
Ve Forschungszentrum Biotechnologie |
Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
|
US4767704A
(en)
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
US4879231A
(en)
|
1984-10-30 |
1989-11-07 |
Phillips Petroleum Company |
Transformation of yeasts of the genus pichia
|
US4970198A
(en)
|
1985-10-17 |
1990-11-13 |
American Cyanamid Company |
Antitumor antibiotics (LL-E33288 complex)
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
FR2596047B1
(fr)
|
1986-03-21 |
1988-05-13 |
Charbonnages Ste Chimique |
Procede de production de styrene
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
GB8610600D0
(en)
|
1986-04-30 |
1986-06-04 |
Novo Industri As |
Transformation of trichoderma
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
US5079233A
(en)
|
1987-01-30 |
1992-01-07 |
American Cyanamid Company |
N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5053394A
(en)
|
1988-09-21 |
1991-10-01 |
American Cyanamid Company |
Targeted forms of methyltrithio antitumor agents
|
EP0435911B1
(en)
|
1988-09-23 |
1996-03-13 |
Cetus Oncology Corporation |
Cell culture medium for enhanced cell growth, culture longevity and product expression
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5688666A
(en)
|
1988-10-28 |
1997-11-18 |
Genentech, Inc. |
Growth hormone variants with altered binding properties
|
WO1990005144A1
(en)
|
1988-11-11 |
1990-05-17 |
Medical Research Council |
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
FR2646437B1
(fr)
|
1989-04-28 |
1991-08-30 |
Transgene Sa |
Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
|
EP0402226A1
(en)
|
1989-06-06 |
1990-12-12 |
Institut National De La Recherche Agronomique |
Transformation vectors for yeast yarrowia
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
DK0479909T3
(da)
|
1989-06-29 |
1997-04-07 |
Medarex Inc |
Bispecifikke reagenser til AIDS-behandling
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5112596A
(en)
|
1990-04-23 |
1992-05-12 |
Alkermes, Inc. |
Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
|
US5268164A
(en)
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US5723286A
(en)
|
1990-06-20 |
1998-03-03 |
Affymax Technologies N.V. |
Peptide library and screening systems
|
WO1992000373A1
(en)
|
1990-06-29 |
1992-01-09 |
Biosource Genetics Corporation |
Melanin production by transformed microorganisms
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
DK0546073T3
(da)
|
1990-08-29 |
1998-02-02 |
Genpharm Int |
Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
ATE164395T1
(de)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
US20030206899A1
(en)
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
CA2108147C
(en)
|
1991-04-10 |
2009-01-06 |
Angray Kang |
Heterodimeric receptor libraries using phagemids
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
DK0590058T3
(da)
|
1991-06-14 |
2004-03-29 |
Genentech Inc |
Humaniseret heregulin-antistof
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
EP0605522B1
(en)
|
1991-09-23 |
1999-06-23 |
Medical Research Council |
Methods for the production of humanized antibodies
|
US5362852A
(en)
|
1991-09-27 |
1994-11-08 |
Pfizer Inc. |
Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
US5270170A
(en)
|
1991-10-16 |
1993-12-14 |
Affymax Technologies N.V. |
Peptide library and screening method
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
ES2241710T3
(es)
|
1991-11-25 |
2005-11-01 |
Enzon, Inc. |
Procedimiento para producir proteinas multivalentes de union a antigeno.
|
US5667988A
(en)
|
1992-01-27 |
1997-09-16 |
The Scripps Research Institute |
Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
|
EP0625200B1
(en)
|
1992-02-06 |
2005-05-11 |
Chiron Corporation |
Biosynthetic binding protein for cancer marker
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
ATE191853T1
(de)
|
1992-07-27 |
2000-05-15 |
Us Health |
Zielgerichte liposome zur blut-hirne schranke
|
CA2140280A1
(en)
|
1992-08-17 |
1994-03-03 |
Avi J. Ashkenazi |
Bispecific immunoadhesins
|
DE69233803D1
(de)
|
1992-10-28 |
2011-03-31 |
Genentech Inc |
Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
|
ATE196606T1
(de)
|
1992-11-13 |
2000-10-15 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
DK0672142T3
(da)
|
1992-12-04 |
2001-06-18 |
Medical Res Council |
Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
EP0714409A1
(en)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Antibodies
|
US5635388A
(en)
|
1994-04-04 |
1997-06-03 |
Genentech, Inc. |
Agonist antibodies against the flk2/flt3 receptor and uses thereof
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
DE69637481T2
(de)
|
1995-04-27 |
2009-04-09 |
Amgen Fremont Inc. |
Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
|
AU2466895A
(en)
|
1995-04-28 |
1996-11-18 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
ES2169864T3
(es)
|
1996-05-31 |
2002-07-16 |
Health Research Inc |
Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
|
US6498236B1
(en)
|
1996-08-30 |
2002-12-24 |
Upfront Chromatography A/S |
Isolation of immunoglobulins
|
ATE387495T1
(de)
|
1996-12-03 |
2008-03-15 |
Amgen Fremont Inc |
Vollkommen humane antikörper die egfr binden
|
US20080318254A9
(en)
|
1997-03-10 |
2008-12-25 |
The Regents Of The University Of California |
PSCA antibodies and hybridomas producing them
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
AU743758B2
(en)
|
1997-04-07 |
2002-02-07 |
Genentech Inc. |
Anti-VEGF antibodies
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
EP0971959B1
(en)
*
|
1997-04-07 |
2005-12-28 |
Genentech, Inc. |
Humanized antibodies and methods for forming humanized antibodies
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
EP0994903B1
(en)
|
1997-06-24 |
2005-05-25 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
PT1034298E
(pt)
|
1997-12-05 |
2012-02-03 |
Scripps Research Inst |
Humanização de anticorpo murino
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
IL138608A0
(en)
|
1998-04-02 |
2001-10-31 |
Genentech Inc |
Antibody variants and fragments thereof
|
WO1999054342A1
(en)
|
1998-04-20 |
1999-10-28 |
Pablo Umana |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
US6811992B1
(en)
|
1998-05-14 |
2004-11-02 |
Ya Fang Liu |
Method for identifying MLK inhibitors for the treatment of neurological conditions
|
ES2241316T3
(es)
|
1998-08-26 |
2005-10-16 |
Cephalon, Inc. |
Modulacion de proteinas quinasa de linaje multiple.
|
WO2000034337A1
(en)
|
1998-12-10 |
2000-06-15 |
Tsukuba Research Laboratory, Toagosei Co., Ltd. |
Humanized monoclonal antibodies against vascular endothelial cell growth factor
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
AU754808B2
(en)
|
1999-03-30 |
2002-11-28 |
Amgen Fremont Inc. |
Method for preparing Monoclonal Antibody
|
ES2420835T3
(es)
|
1999-04-09 |
2013-08-27 |
Kyowa Hakko Kirin Co., Ltd. |
Procedimiento para controlar la actividad de las moléculas inmunofuncionales
|
JP4926320B2
(ja)
|
1999-04-28 |
2012-05-09 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
Vegfの選択的阻害による癌処置のための組成物および方法
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
ATE303445T1
(de)
|
1999-10-04 |
2005-09-15 |
Medicago Inc |
Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
|
JP4668498B2
(ja)
|
1999-10-19 |
2011-04-13 |
協和発酵キリン株式会社 |
ポリペプチドの製造方法
|
ATE315789T1
(de)
|
1999-11-16 |
2006-02-15 |
Genentech Inc |
Elisa für vegf
|
IL152794A0
(en)
|
2000-06-23 |
2003-06-24 |
Schering Ag |
Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use
|
US6514221B2
(en)
|
2000-07-27 |
2003-02-04 |
Brigham And Women's Hospital, Inc. |
Blood-brain barrier opening
|
US20020065259A1
(en)
|
2000-08-30 |
2002-05-30 |
Schatzberg Alan F. |
Glucocorticoid blocking agents for increasing blood-brain barrier permeability
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
CN103333860B
(zh)
|
2000-10-06 |
2015-07-08 |
协和发酵麒麟株式会社 |
产生抗体组合物的细胞
|
US7034036B2
(en)
|
2000-10-30 |
2006-04-25 |
Pain Therapeutics, Inc. |
Inhibitors of ABC drug transporters at the blood-brain barrier
|
US20030083299A1
(en)
|
2000-11-04 |
2003-05-01 |
Ferguson Ian A. |
Non-invasive delivery of polypeptides through the blood-brain barrier
|
SE0100569D0
(sv)
|
2001-02-20 |
2001-02-20 |
Astrazeneca Ab |
New compounds
|
AU2002257142B2
(en)
|
2001-04-13 |
2008-09-04 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US7667004B2
(en)
*
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
DE10121982B4
(de)
|
2001-05-05 |
2008-01-24 |
Lts Lohmann Therapie-Systeme Ag |
Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
|
WO2002092017A2
(en)
|
2001-05-16 |
2002-11-21 |
Albert Einstein College Of Medicine Of Yeshiva University |
Human antipneumococcal antibodies from non-human animals
|
ATE445838T1
(de)
|
2001-07-25 |
2009-10-15 |
Raptor Pharmaceutical Inc |
Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
|
AU2002339845B2
(en)
|
2001-08-03 |
2009-03-26 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
BR0212136A
(pt)
|
2001-08-23 |
2004-12-07 |
Genmab As |
Anticorpo monoclonal humano isolado, métodos para inibir a produção de tnfa em células t ou monócitos e a proliferação de célula t, hibridoma, transfectoma, animal não humano transgênico, método para produzir um anticorpo monoclonal humano, composição farmacêutica, métodos para tratar ou prevenir um distúrbio mediado pela il-15 humana, a psorìase e a artrite reumatóide, método para diagnosticar uma doença, ácido nucleico, e, vetor de expressão
|
MXPA04003798A
(es)
|
2001-10-25 |
2004-07-30 |
Genentech Inc |
Composiciones de glicoproteina.
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
US20030162695A1
(en)
|
2002-02-27 |
2003-08-28 |
Schatzberg Alan F. |
Glucocorticoid blocking agents for increasing blood-brain barrier permeability
|
US7351729B2
(en)
|
2002-03-08 |
2008-04-01 |
Signal Pharmaceuticals, Llc |
JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
|
CA2492671C
(en)
|
2002-03-22 |
2012-04-17 |
Aprogen, Inc. |
Humanized antibody and process for preparing same
|
EA200401325A1
(ru)
|
2002-04-09 |
2005-04-28 |
Киова Хакко Когио Ко., Лтд. |
Клетки с модифицированным геномом
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
WO2003085118A1
(fr)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede de production de composition anticorps
|
CA2481658A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to fcy receptor iiia
|
AU2003236019A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
|
US7691568B2
(en)
|
2002-04-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Antibody composition-containing medicament
|
EP1551793B1
(en)
|
2002-06-19 |
2016-01-20 |
AmKor Pharma, Inc. |
Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
|
EP1391213A1
(en)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
AU2003302676A1
(en)
|
2002-12-03 |
2004-06-23 |
Blanchette Rockefeller Neurosciences Institute |
Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
|
SI1572744T1
(sl)
|
2002-12-16 |
2010-09-30 |
Genentech Inc |
Imunoglobulinske variante in njihove uporabe
|
AU2004205898B2
(en)
|
2003-01-17 |
2009-11-19 |
The Research Foundation Of State University Of New York |
Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
|
WO2005000200A2
(en)
|
2003-05-09 |
2005-01-06 |
Sugen, Inc. |
Novel kinases
|
MXPA05012571A
(es)
|
2003-05-21 |
2006-02-08 |
Medarex Inc |
Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
|
PT1638941E
(pt)
|
2003-05-22 |
2010-08-24 |
Abbott Lab |
Inibidores de quinases de indazole, benzisoxazole e benzisotiazole
|
NZ621449A
(en)
*
|
2003-05-30 |
2015-07-31 |
Genentech Inc |
Treatment with anti-vegf antibodies
|
WO2005003762A2
(en)
|
2003-06-17 |
2005-01-13 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with sensory neuron-specific g protein-coupled receptor 2 (snsr2)
|
US20050043264A1
(en)
|
2003-07-01 |
2005-02-24 |
Jyh-Lyh Juang |
Methods of inhibiting neurodegenerative disease
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
KR20060069825A
(ko)
|
2003-08-01 |
2006-06-22 |
제넨테크, 인크. |
제한된 다양성을 갖는 항체 cdr 폴리펩티드 서열
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
EP1677739A4
(en)
|
2003-09-04 |
2008-07-23 |
Immusol Inc |
METHODS FOR IDENTIFYING AGENTS THAT INHIBIT THE GROWTH OF CANCER CELLS
|
WO2005025511A2
(en)
|
2003-09-10 |
2005-03-24 |
Cedars-Sinai Medical Center |
Potassium channel mediated delivery of agents through the blood-brain barrier
|
AU2004279742A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Fused protein composition
|
US20070134759A1
(en)
|
2003-10-09 |
2007-06-14 |
Harue Nishiya |
Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
|
TR201809892T4
(tr)
|
2003-11-05 |
2018-07-23 |
Roche Glycart Ag |
Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
US7241779B2
(en)
|
2003-12-23 |
2007-07-10 |
Cephalon, Inc. |
Fused pyrrolocarbazoles
|
US7169802B2
(en)
|
2003-12-23 |
2007-01-30 |
Cephalon, Inc. |
Fused pyrrolocarbazoles
|
US7833722B2
(en)
|
2004-04-27 |
2010-11-16 |
Takeda Pharmaceutical Company Limited |
Ligands for G protein-coupled receptor protein and use thereof
|
MXPA06014421A
(es)
|
2004-06-10 |
2007-05-04 |
Regeneron Pharma |
Uso de inhibidores de vegf para el tratamiento de cancer humano.
|
BRPI0518105A
(pt)
*
|
2004-12-17 |
2008-11-04 |
Genentech Inc |
uso de antagonista da angiogênese e uso de anticorpo anti-vegf
|
US7449442B2
(en)
|
2005-07-12 |
2008-11-11 |
Children's Medical Center Corporation |
EGFR inhibitors promote axon regeneration
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
ES2322881B1
(es)
|
2005-12-26 |
2010-04-22 |
Consejo Superior Investig. Cientificas |
Uso de compuestos agonistas de la actividad pi3k en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y sus aplicaciones en el tratamiento de enfermedades neurodegenerativas.
|
US20080051319A1
(en)
|
2006-08-22 |
2008-02-28 |
Children's Medical Center Corporation |
Inhibiting JNK Signaling Promotes CNS Axon Regeneration
|
WO2008024776A1
(en)
|
2006-08-22 |
2008-02-28 |
Children's Medical Center Corporation |
Inhibiting jnk signaling promotes cns axon regeneration
|
US7841282B2
(en)
*
|
2006-09-21 |
2010-11-30 |
John Kimberlin |
Apparatus, system, and method for operating and controlling combustor for ground or particulate biomass
|
ES2582656T3
(es)
|
2006-12-19 |
2016-09-14 |
Genentech, Inc. |
Antagonistas específicos del VEGF para terapia adyuvante y neoadyuvante, y el tratamiento de tumores en fase temprana
|
TWI580694B
(zh)
*
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
WO2009143865A1
(en)
|
2008-05-30 |
2009-12-03 |
Xigen S.A. |
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
|
US20100056609A1
(en)
|
2008-08-26 |
2010-03-04 |
Washington University |
Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway
|
MX2011004306A
(es)
|
2008-10-22 |
2011-07-28 |
Genentech Inc |
Modulacion de degeneracion de axones.
|
US9048685B2
(en)
|
2012-01-20 |
2015-06-02 |
Alex Huang |
Emergency lighting with charging indicator circuitry
|